I currently use genetic engineering tools to create novel gene and cell therapies to regenerate the kidney. My primary research interest is in translational applications of gene transfer in organ regeneration, transcription factor reprogramming, stem cell therapy, and kidney disease. We deliver transcription factors to reprogram adult cells into induced nephron progenitors in the kidney. Additionally, we are modifying human urine-derived stem cells to regenerate the kidney after injury. Studies of transposase self-regulation with the TcBuster transposon system provide new insights into how transposons function. Guided by new findings, we will engineer innovative therapies for kidney disease.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo. O'Neil RT, Saha S, Veach RA, Welch RC, Woodard LE, Rooney CM, Wilson MH (2018) Nat Commun 9(1): 1325
    › Primary publication · 29636469 (PubMed) · PMC5893599 (PubMed Central)
  2. Hydrodynamic Renal Pelvis Injection for Non-viral Expression of Proteins in the Kidney. Woodard LE, Welch RC, Williams FM, Luo W, Cheng J, Wilson MH (2018) J Vis Exp (131)
    › Primary publication · 29364221 (PubMed) · PMC5907682 (PubMed Central)
  3. Comparative analysis of chimeric ZFP-, TALE- and Cas9-piggyBac transposases for integration into a single locus in human cells. Luo W, Galvan DL, Woodard LE, Dorset D, Levy S, Wilson MH (2017) Nucleic Acids Res 45(14): 8411-8422
    › Primary publication · 28666380 (PubMed) · PMC5737283 (PubMed Central)
  4. Kidney-specific transposon-mediated gene transfer in vivo. Woodard LE, Cheng J, Welch RC, Williams FM, Luo W, Gewin LS, Wilson MH (2017) Sci Rep : 44904
    › Primary publication · 28317878 (PubMed) · PMC5357952 (PubMed Central)
  5. Temporal self-regulation of transposition through host-independent transposase rodlet formation. Woodard LE, Downes LM, Lee YC, Kaja A, Terefe ES, Wilson MH (2017) Nucleic Acids Res 45(1): 353-366
    › Primary publication · 27899587 (PubMed) · PMC5224482 (PubMed Central)
  6. piggyBac-ing models and new therapeutic strategies. Woodard LE, Wilson MH (2015) Trends Biotechnol 33(9): 525-33
    › Primary publication · 26211958 (PubMed) · PMC4663986 (PubMed Central)
  7. Protective role of insulin-like growth factor-1 receptor in endothelial cells against unilateral ureteral obstruction-induced renal fibrosis. Liang M, Woodard LE, Liang A, Luo J, Wilson MH, Mitch WE, Cheng J (2015) Am J Pathol 185(5): 1234-50
    › Primary publication · 25783760 (PubMed) · PMC4419212 (PubMed Central)
  8. Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells. Saha S, Woodard LE, Charron EM, Welch RC, Rooney CM, Wilson MH (2015) Nucleic Acids Res 43(3): 1770-82
    › Primary publication · 25605795 (PubMed) · PMC4330379 (PubMed Central)
  9. Two Arabidopsis loci encode novel eukaryotic initiation factor 4E isoforms that are functionally distinct from the conserved plant eukaryotic initiation factor 4E. Patrick RM, Mayberry LK, Choy G, Woodard LE, Liu JS, White A, Mullen RA, Tanavin TM, Latz CA, Browning KS (2014) Plant Physiol 164(4): 1820-30
    › Primary publication · 24501003 (PubMed) · PMC3982745 (PubMed Central)
  10. An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression. Doherty JE, Woodard LE, Bear AS, Foster AE, Wilson MH (2013) FASEB J 27(9): 3753-62
    › Primary publication · 23752206 (PubMed) · PMC3752539 (PubMed Central)
  11. Comparative analysis of the recently discovered hAT transposon TcBuster in human cells. Woodard LE, Li X, Malani N, Kaja A, Hice RH, Atkinson PW, Bushman FD, Craig NL, Wilson MH (2012) PLoS One 7(11): e42666
    › Primary publication · 23166581 (PubMed) · PMC3499496 (PubMed Central)
  12. Loss of glutathione S-transferase A4 accelerates obstruction-induced tubule damage and renal fibrosis. Liang A, Wang Y, Woodard LE, Wilson MH, Sharma R, Awasthi YC, Du J, Mitch WE, Cheng J (2012) J Pathol 228(4): 448-58
    › Primary publication · 22711583 (PubMed) · PMC3760987 (PubMed Central)
  13. Long-term phenotypic correction in factor IX knockout mice by using ΦC31 integrase-mediated gene therapy. Keravala A, Chavez CL, Hu G, Woodard LE, Monahan PE, Calos MP (2011) Gene Ther 18(8): 842-8
    › Primary publication · 21412285 (PubMed) · PMC6070132 (PubMed Central)
  14. Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. Woodard LE, Keravala A, Jung WE, Wapinski OL, Yang Q, Felsher DW, Calos MP (2010) PLoS One 5(6): e11367
    › Primary publication · 20614008 (PubMed) · PMC2894073 (PubMed Central)
  15. Kinetics and longevity of ΦC31 integrase in mouse liver and cultured cells. Chavez CL, Keravala A, Woodard LE, Hillman RT, Stowe TR, Chu JN, Calos MP (2010) Hum Gene Ther 21(10): 1287-97
    › Primary publication · 20497035 (PubMed) · PMC2974851 (PubMed Central)
  16. Effect of nuclear localization and hydrodynamic delivery-induced cell division on phiC31 integrase activity. Woodard LE, Hillman RT, Keravala A, Lee S, Calos MP (2010) Gene Ther 17(2): 217-26
    › Primary publication · 19847205 (PubMed) · PMC2820593 (PubMed Central)
  17. Mutational derivatives of PhiC31 integrase with increased efficiency and specificity. Keravala A, Lee S, Thyagarajan B, Olivares EC, Gabrovsky VE, Woodard LE, Calos MP (2009) Mol Ther 17(1): 112-20
    › Primary publication · 19002165 (PubMed) · PMC2834998 (PubMed Central)